• Revenue increased 13.1% to $60.7 million
• Profit before tax up 40% to $2.1 million
• No dividend declared for the half year

SomnoMed Limited, a public company providing treatment solutions for sleep-related breathing disorders, has released its half-year report for the six months ended 31 December 2025. The company reported a 13.1% increase in revenue from ordinary activities to $60.7 million, compared to $53.7 million in the previous corresponding period. Profit from ordinary activities before tax attributable to members increased by 40% to $2.1 million, up from $1.5 million in the prior half year. Profit after income tax from continuing operations was $792,000, compared to a loss of $106,000 in the previous corresponding period. The Board has resolved that no dividend will be paid for the half year ended 31 December 2025. The company will continue to produce and sell devices for the oral treatment of sleep-related disorders in Australia and overseas.